Today: 3 November 2025
Subscribe
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React
 ·  ·  ·  ·  · 

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

by
3 November 2025
  • New GLP-1 “microdose” program: Telehealth company Hims & Hers (NYSE: HIMS) announced on Oct 29, 2025 that it will begin offering clinician-supervised compounded GLP-1 microdosing plans to address metabolic health beyond BMI [1] [2]. The plans use ultra-low doses of semaglutide (same as Ozempic/Wegovy) tailored to patients with risk factors like sleep apnea or high blood pressure [3].
  • Program details: Hims’ doctors tout emerging research that GLP-1 drugs lower inflammation markers independent of weight loss, and see microdosing as a way to “minimize side effects” and improve adherence [4] [5]. The six-month microdose package will cost $1,200 upfront [6], matching Hims’ existing compounded GLP-1 offerings. (By comparison, Novo Nordisk’s Wegovy is over $900/month retail.) All dispensed drugs require prescription and come from licensed pharmacies, though Hims notes these compounds “are not reviewed for safety or efficacy by the FDA” [7].
  • Expert views – cautious balance: Hims’ medical lead stresses microdosing is “early-stage” but promising [8]. However, independent experts warn evidence is lacking. Endocrinologists emphasize that microdosing is not FDA-approved and safety data are scarce. For example, one obesity specialist notes that giving smaller GLP-1 doses can still cause side effects (nausea, gut issues, etc.) and that compounded formulations carry unknown risks [9]. A Hackensack Meridian endocrinologist bluntly states safety “is unknown” without formal studies [10]. Others echo that microdosing might work for maintenance or minor weight goals, but “it may not be as effective” as full doses for major weight loss [11]. Nutrition experts caution patients to vet sources carefully, since compounded semaglutide isn’t FDA-tested [12] [13].
  • Regulatory context: In early 2025 the FDA ended the Ozempic/Wegovy shortage and told compounders (like Hims) to stop copying GLP-1 injectables [14]. Hims had been a big seller of such “copycat” weight-loss shots ($199/month vs brand $900) [15], but the company said it would phase those out after FDA’s update [16]. Instead, Hims pivoted to a new partnership with Novo Nordisk to bundle brand Wegovy via its platform (at $599/month total) [17]. Now, Hims’ microdosing uses compounded semaglutide at lower doses – a legal gray zone that regulators are monitoring. Notably, Hims’ press release explicitly warns: “Compounded drug products are not approved or evaluated for safety… by the FDA” [18]. This reflects broader warnings (FDA and medical groups have flagged counterfeit/compounded GLP-1 risks) [19] [20].
  • Stock reaction & market: HIMS stock (~$45 as of early Nov. 2025) is volatile but up about +87% year-to-date [21]. A late-Oct bump (+2–3%) followed news that JPMorgan bought up ~17.8M shares (~8.1% of HIMS) [22]. However, the stock had slipped ~20% in October amid CEO share sales (Andrew Dudum sold ~$11M, per SEC filings [23]) and regulatory uncertainty. Wall Street consensus is cautious: analysts rate HIMS a Hold (8 holds, 2 buys, 2 sells) [24] with an average price target ~$49.75 (≈9% above current) [25]. After Q2’s growth slowdown, Q3 ’25 estimates foresee ~$580 million revenue (+40% YoY) and ~$0.09 EPS [26]. The options market is braced for a ~15% stock swing around the Nov 3 earnings release [27] [28].
  • Broader strategy: Beyond weight loss, Hims has been rapidly expanding its telehealth offerings. In late 2025 it launched a women’s menopause/perimenopause specialty (aiming for $1 billion Hers revenue by 2026) [29], and a men’s health category with new branded oral testosterone (KYZATREX®) and compounded hormone therapies [30] [31]. CEO Dudum emphasizes “access and affordability” across these initiatives. Hims also continues a weight-loss collaboration with Novo Nordisk (Wegovy bundles) [32] and claims 2.4M subscribers globally.

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income [33]. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 [34], and free cash flow turning positive in 2025 [35]. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty [36]. Key analysts (TD Cowen, KeyBanc) maintain Holds in light of decelerating growth and competition, though they acknowledge solid subscription volumes and expanding offerings [37].

Bottom line: Hims & Hers is front-running the latest GLP-1 craze by marketing a “microdose” treatment, betting it can carve out a niche in preventive metabolic care [38] [39]. Medical experts see both potential (earlier intervention, fewer side effects) and pitfalls (lack of data, safety unknown) [40] [41]. Investors will be watching its Nov. 3 earnings for any sign that these new services boost subscriber growth or cross-selling, against a backdrop of intense industry competition (Lilly/Novo, other telehealth, insurance pressures). With consensus targets only modestly above current levels [42], the stock’s future hinges on execution across weight loss, men’s and women’s health, and how regulators treat compounded GLP-1 therapies. In Dr. Primack’s words: “microdosing is an important step for metabolic health,” but analysts and FDA observers alike urge caution until real-world outcomes emerge [43] [44].

Sources: Hims & Hers press release [45] [46]; TipRanks analysis [47] [48]; SimplyWallSt data [49] [50]; Financial Press (Economic Times, Business Insider) [51] [52]; Fox News health reports [53]; Medical News Today [54] [55]; Sherwood News (investor news) [56].

Dr. Craig Primack talks Hims & Hers launching its own GLP-1 offering as demand rises
Watch this video on YouTube.

References

1. news.hims.com, 2. www.tipranks.com, 3. news.hims.com, 4. news.hims.com, 5. news.hims.com, 6. www.tipranks.com, 7. news.hims.com, 8. news.hims.com, 9. www.medicalnewstoday.com, 10. www.medicalnewstoday.com, 11. www.medicalnewstoday.com, 12. www.medicalnewstoday.com, 13. www.medicalnewstoday.com, 14. www.businessinsider.com, 15. www.businessinsider.com, 16. www.businessinsider.com, 17. www.businesswire.com, 18. news.hims.com, 19. www.foxnews.com, 20. www.foxnews.com, 21. www.tipranks.com, 22. muckrack.com, 23. economictimes.indiatimes.com, 24. www.tipranks.com, 25. www.tipranks.com, 26. www.tipranks.com, 27. www.tipranks.com, 28. www.tipranks.com, 29. www.businesswire.com, 30. www.businesswire.com, 31. www.businesswire.com, 32. www.businesswire.com, 33. simplywall.st, 34. www.tipranks.com, 35. simplywall.st, 36. simplywall.st, 37. www.tipranks.com, 38. news.hims.com, 39. www.tipranks.com, 40. www.medicalnewstoday.com, 41. news.hims.com, 42. www.tipranks.com, 43. news.hims.com, 44. www.medicalnewstoday.com, 45. news.hims.com, 46. news.hims.com, 47. www.tipranks.com, 48. www.tipranks.com, 49. simplywall.st, 50. simplywall.st, 51. economictimes.indiatimes.com, 52. www.businessinsider.com, 53. www.foxnews.com, 54. www.medicalnewstoday.com, 55. www.medicalnewstoday.com, 56. muckrack.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. Ford Stock Surges on Q3 Earnings Beat – EV Slowdown & 2025 Outlook Revealed
  2. Epic 2025 Comeback: Intel Stock Soars – Latest Price, News & Forecast
  3. Sudden Southern Park Mall Shutdown Shocks Community – Safety Scare, Unpaid Bills & Uncertain Future
  4. AMD Stock Skyrockets on AI Mega-Deal – Latest Price, Q3 Earnings Preview & Expert Analysis

Stock Market Today

  • AMH Hits Oversold RSI 29.8: Potential Buy Signal for American Homes 4 Rent
    November 3, 2025, 5:20 PM EST. Legendary investor Warren Buffett cautions to be fearful when others are greedy. For American Homes 4 Rent (AMH), the RSI dipped into oversold territory at 29.8 on Monday, with the stock trading as low as $31.01. By comparison, the SPY RSI stood around 61.3, signaling broader momentum. The reading could imply that recent selling is exhausting and may set up a short-term buying opportunity for AMH. The chart places AMH's 52-week range low at $31.01 and high at $39.49, versus a last trade near $31.53. Investors might wait for a confirmation before entering, mindful that an oversold condition does not guarantee a rebound.
  • Tripadvisor (TRIP) Falls Below 200-Day Moving Average
    November 3, 2025, 5:18 PM EST. Tripadvisor Inc. (TRIP) slid below its 200-day moving average of $15.59 on Monday, trading as low as $15.39. The shares were down about 3% for the session. The chart shows the stock's one-year performance versus the 200 DMA, with a 52-week range of $10.43 to $20.16 and a last trade near $15.67. A cross below the 200 DMA can signal a near-term momentum shift, though traders will watch how the price handles the area around $15.59. If the area holds, a bounce could follow; if not, further weakness could unfold as investors reassess the setup.
  • Lowe's (LOW) RSI Drops to 27.2, Enters Oversold Territory
    November 3, 2025, 5:16 PM EST. Legendary investor Warren Buffett's maxim aside, Lowe's Companies Inc (LOW) slipped into oversold territory as its Relative Strength Index (RSI) tumbled to 27.2 on Thursday. The stock traded as low as $224.07, well below the 52-week high of $263.31 and near the year's lows. Compared with the SPDR S&P 500 ETF (SPY), which posted an RSI of 36.3, LOW's momentum appears more negative in the near term. An oversold reading like 27.2 can be read as a sign that the recent selling pressure could be stabilizing, potentially creating an entry point for a rebound. The chart shows LOW's 52-week range from a low of $150.84 to a high of $263.31, with the latest trade around $223.93. Investors are watching for follow-through moves.
  • Dollar Edges Higher as Yields Rise; PMI Data and ECB Divergence Shape the Outlook
    November 3, 2025, 5:14 PM EST. The dollar edged higher (+0.06%) as the 10-year yield rose ~2.5 bps, lifting rate differentials. Powell's warning that a December cut isn't guaranteed keeps the Fed in view. Data were mixed: the ISM manufacturing PMI slipped to 48.7 (miss) while the final Oct PMI rose to 52.5, offering mixed signals. Fed Governor Miran urged a less restrictive stance, easing some hawkish pressure. Amid ongoing government shutdown concerns, markets still priced roughly a 66% chance of a 25 bp FOMC cut in December. EUR/USD weakened on dollar strength, with ECB divergence supportive for the euro. Gold (+0.99%) and silver (+0.53%) found support, though higher yields remain a headwind. USD/JPY consolidated below an 8.5-month high, as the yen remained fragile amid political uncertainty.
  • Nasdaq Warns TON Strategy Over $558M PIPE for Toncoin Purchase
    November 3, 2025, 5:12 PM EST. TON Strategy (formerly Verb Technology) drew a warning from Nasdaq for violating shareholder approval rules after privately raising about $558 million via a PIPE to buy Toncoin. Nasdaq said the company did not intentionally evade compliance, but failed to obtain required approvals for both the PIPE and a later Toncoin purchase with proceeds, and opted for a warning rather than delisting. The episode underscores how, in crypto-fueled moves, firms rush into large crypto treasuries to lift stock price. The stock rose past $22 on the pivot before fading, and the shares are reported to have fallen more than 80% from the highs as hype faded and volatility persisted.
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?
Previous Story

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive
Next Story

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

Related Articles

Go toTop